Create new account

Publications

-------

Peer-reviewed papers

Wisniowska B, Tylutki Z, Polak S. Thorough QT (TQT) studies: Concordance with torsadogenesis and evolving cardiac safety testing paradigm. Drug Discovery Today, 2017, In press.

Tylutki Z, Polak S. A four-compartment PBPK heart model accounting for cardiac metabolism - model development and applicationNature Scientific Reports, 2017, Scientific Reports 7, Article number: 39494.

Abbasi M, Patel N, Small B, Jamei M, Polak S. Early assessment of pro-arrhythmic risk of drugs using the in vitro data and single cell based in silico models: proof of concept Toxicology Mechanisms and Methods, 2017, 27(2):88-99.

Wisniowska B, Polak S. So am I or am I not proarrhythmic? Comparison of various classifications of drugs TdP propensity. Drug Discovery Today, 2017,22(1):10–16.

Wisniowska B, Polak S. The role of interaction model in simulation of drug interactions and QT prolongation Current Pharmacology Reports, 2016,2(6): 339-344.

Wisniowska B, Polak S. Virtual clinical trial towards polytherapy safety assessment – combination of PBPK/PD based modelling and simulation approach with DDIs involving terfenadine as an example. Journal of Pharmaceutical Sciences, 2016,105(11): 3415-3424.

Tylutki Z, Polak S, Wisniowska B. Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling & Simulations. Current Pharmacology Reports, 2016,2(14): 171-177.

Wisniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect - comprehensive overview of clinical trials. BMC Pharmacology and Toxicology, 2016,17(12).

Tylutki Z, Polak S. The effect of increasing amitriptyline doses on cardiomyocytes’ electrophysiology – simulation study. Bio-Algorithms and Med-Systems, 2016, 12(1):33-38.

Badyra B, Lisowski B, Polak S, Kudolo J, Wiśniowska B. How in vitro influences in silico utilized for the prediction of in vivo — pilot study of the drug-induced pro-arrhythmic potency prediction. Folia Medica Cracoviensia, 2015,LV(4): 5-19.

Mendyk A, Güres A, Jachowicz R, Szlęk J, Polak S, Wisniowska B, Kleinebudde P. From Heuristic to Mathematical Modeling of Drugs Dissolution Profiles: Application of Artificial Neural Networks (ANNs) and Genetic Programming (GP). Computational and Mathematical Methods in Medicine, 2015, Article ID 863874.

Culen M, Tuszyński PK, Polak S, Jachowicz R, Mendyk A, Dohnal J. Development of In Vitro-In Vivo Correlation/Relationship Modeling Approaches for Immediate Release Formulations Using Compartmental Dynamic Dissolution Data from ‘‘Golem’’: A Novel Apparatus). BioMed Research International, 2015, Article ID 328628.

Polak S, Pugsley MK, Stockbridge N, Garnett C, Wisniowska B. Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates. AAPS Journal, 2015; 17(4): 1025-1032.

Tylutki Z, Polak S. Plasma vs. heart tissue concentration in humans – literature data analysis of drugs distribution. Biopharmaceutics and Drug Disposition, 2015; 36(6): 337–351.

Glinka A, Polak S. QTc modification after risperidone administration – insight into the mechanism of action with use of the modeling and simulation at the population level approachToxicology Mechanisms and Methods, 2015; 25(4): 279-286.

Wisniowska B, Mendyk A, Szlęk J, Kołaczkowski M, Polak S. Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents. Journal of Applied Toxicology, 2015; 35(9): 1030–1039.

Mishra H, Polak S, Jamei M, Rostami-Hodjegan A. Interaction Between Domperidone and Ketoconazole: Toward Prediction of Consequent QTc Prolongation Using Purely In Vitro Information.  CPT Pharmacometrics Syst. Pharmacol., 2014; 3, e130.

Fijorek K, et al. Model of the distribution of diastolic left ventricular posterior wall thickness in healthy adults and its impact on the behavior of a string of virtual cardiomyocytes. Journal of Cardiovascular Translational Research, 2014; 7(5): 507-517.

Fijorek K, Püsküllüoglu M, Tomaszewski R, Tomaszewska D, Glinka A, Polak S. Serum potassium, sodium and calcium levels in healthy individuals – literature review and data analysis. Folia Medica Cracoviensia, 2014; LIV(1): 53-70.

Glinka A, Polak S. The Effects of Six Antipsychotic Agents on QTc - an attempt to mimic clinical trial through simulation including variability in the population. Computers in Biology and Medicine, 2014; 7:20-26.

Wisniowska B, Mendyk A, Fijorek K, Polak S. Computer-based prediction of the drug proarrhythmic effect - problems, issues, known and suspected challenges Europace, 2014, 16:724-735.

Polak S, Wisniowska B, Fijorek K, Glinka A, Mendyk A. In vitro - in vivo extrapolation of drug-induced proarrhythmia predictions at the population level. Drug Discovery Today, 2014; 19:275-281.

Glinka A, Polak S. An analysis of cardiomyocyte electrophysiology in the presence of hERG gene mutations. Bio-Algorithms and Med-Systems, 2013; 9(3):135-140.

Fijorek K, Püsküllüoglu M, Polak S. Circadian models of serum potassium, sodium and calcium concentrations in healthy individuals, and their application to cardiac electrophysiology simulations at individual levelComputational and Mathematical Methods in Medicine, 2013; Article ID 429037, 8 pages, 2013. doi:10.1155/2013/429037.

Mendyk A, Tuszyński P, Polak S, Jachowicz R. In vitro-in vivo relationship (IVIVR) generalized model based on artificial neural networksJournal of Drug Design, Development and Therapy, 2013;7:223-232.

Fijorek K, Patel N, Klima Ł, Stolarz-Skrzypek K, Kawecka-Jaszcz K, Polak S. Age and gender dependent heart rate circadian model development and performance verification on the proarrhythmic drug case studyTheoretical Biology and Medical Modelling, 2013;10:7.

Polak S. In vitro to human in vivo translation – pharmacokinetics and pharmacodynamics of quinidineALTEX, 2013;3(30):309-318.

Glinka A, Polak S. Wild type and K897T polymorphisms of the hERG gene: modeling the AP in Caucasians. Bioinformation, 2012;8(22):1062-1065.

Polak S, Wisniowska B, Glinka A, Polak M. tox-database.net - data describing the chemicals triggered in vitro cardiac ionic channels inhibitionBMC Pharmacology and Toxicology, 2012;13(6).

Wisniowska B, Mendyk A, Fijorek K, Glinka A, Polak S. Predictive model for the L-type channel inhibition - multichannel block in QT prolongation risk assessmentJournal of Applied Toxicology, 2012;32(10):858-866.

Polak S, Fijorek K. Inter-individual variability in the pre-clinical drug cardiotoxic safety assessment - analysis of the age - cardiomyocytes electric capacitance dependence. Journal of Cardiovascular Translational Research, 2012;5(3):321-332.

Polak S, Wisniowska B, Glinka A, Fijorek K, Mendyk A. Slow delayed rectifying potassium current (IKs) – analysis of the in vitro inhibition data and predictive model developmentJournal of Applied Toxicology, 2013;33(8):723-739.

Polak S, Fijorek K, Glinka A, Wisniowska B, Mendyk A. Virtual population generator for human cardiomyocytes parameters. In silico drug cardiotoxicity assessment. Toxicology Mechanisms and Methods, 2012;22(1):31-40.

Fijorek K, Fijorek D, Wisniowska B, Polak S. BDTcomparator: a program for comparing binary classifiersBioinformatics, 2011;27(24):3439-3440.

Fijorek K, Fijorek D. The effectiveness of best subset variable selection in Firth logistic regressionApplied Informatics Methods, 2012;2(27):15-24.

Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A. The open-access dataset for in silico cardiotoxicity prediction systemBioinformation, 2011;6(6):244-245.

Polak S, Wisniowska B, Ahamadi M, Mendyk A. Prediction of the hERG potassium channel inhibition potential with use of Artificial Neural NetworksApplied Soft Computing, 2011;11(2):2611-2617.

Wisniowska B, Mendyk A, Polak M, Szlek J, Polak S. Random Forest based assessment of the hERG channel inhibition potential for the early drug cardiotoxicity testing. Bio-Algorithms and Med-Systems, 2010;6(12):131-136.

Wisniowska B, Polak S. hERG in vitro interchange factors - development and verification. Toxicology Mechanisms and Methods, 2009;19(4):278-284.

Polak S, Wisniowska B, Brandys J. Collation, assessment and analysis of literature in vitro data on hERG receptor blocking potency for subsequent modeling of drugs cardiotoxic properties. Journal of Applied Toxicology, 2009;29(3):183-206.

-------

Books / Proceedings / Conference presentations

Viceconti M, Henney A, Morley-Fletcher E. in silico Clinical Trials: How Computer Simulation will Transform the Biomedical Industry. Research and Technological Development Roadmap, Avicenna Consortium, Brussels Jan 2016.

Wiśniowska B, Badyra B, Lisowski B, Polak S. To sum or not to sum - how to assess torsadogenic potential of combination of drugs and their active metabolites. In vitro assessment with loratadine and desloratadine as the exemplary drugs. Safety Pharmacology Society, Annual Meeting, 28.09-1.10.2015, Prague, Czech Republic.

Wiśniowska B, Badyra B, Lisowski B, Polak S, Glinka A. Systems pharmacology based approach utilized for prediction of the cardiac consequences of drug-drug interactions. Safety Pharmacology Society, Annual Meeting, 28.09-1.10.2015, Prague, Czech Republic.

Polak S. 13th European International Society for the Study of Xenobiotics (ISSX) Meeting June 22 - 25, 2015 in Glasgow, Scotland.

Polak S. IVIV and/or animal/human translations. EUFEPS Annual Meeting 2015 - System Approaches for Better Medicines and Health. 15-17 June 2015, Geneva, Switzerland. Tuesday June 16, Session II: Drug development - predictive toxicology, predictive translations.

Wiśniowska B. Evaluation of the ability of computational IVIV extrapolation to assess pharmacokinetic (Cmax/AUC) and pharmacodynamic (QTc) consequences of drug-drug interactions with cisapride and clarithromycin as exemplary drugs. EUFEPS Annual Meeting 2015 - System Approaches for Better Medicines and Health. 15-17 June 2015, Geneva, Switzerland. Tuesday June 16, Session II: Drug development - predictive toxicology, predictive translations.

Polak S. Physiological-Based Cardiomyocyte Model: Predicting QT Changes in Humans. 2015 ASCPT Annual Meeting. 03-07 March 2015, New Orleans, USA. Tuesday March 3, QUANTITATIVE SYSTEMS PHARMACOLOGY: MULTISCALE MODEL-BASED DRUG DEVELOPMENT THROUGH INTEGRATING SYSTEMS BIOLOGY AND PHARMACOMETRICS.

Polak S. Simulating cardiac consequences of the genetic variability at the metabolism level with use of middle-out approach and flecainide as an example compound. 2015 ASCPT Annual Meeting. 03-07 March 2015, New Orleans, USA. POSTER SESSION.

Polak S, Tylutki Z, Wiśniowska B, Rostami-Hodjegan A. Simulating pharmacokinetic and pharmacodynamic impact of the drug formulation on the human cardiac safety by applying in vitro - in vivo extrapolation approach. AAPS Annual Meeting and Expoition; San Diego, USA; 2-6.11.2014

Patel N., Jamei M., Rostami Hodjegan A., Polak S. Prediction of QT changes in humans incorporating in vitro data into physiologically based cardiomyocyte cell model - a case study on inhibition of multiple cardiac ion currents by tolterodine and its metabolite. 2013 AAPS Annual Meeting and Exposition. 10-14 November 2013, San Antonio, USA. POSTER T3221. Session Date: Tuesday, November 12, 2013 Session Time: 01:30 pm - 04:30 pm. 

Small B., et al. Pharmacokinetic (PK) and Pharmacodynamic (PD) Implications of Diurnal Variation of Gastric Emptying and Small Intestinal Transit Time for Quinidine Mechanistic Simulation. BSTP 28th Annual Scientific Meeting held jointly with the Safety Pharmacology Society. Thursday 14th and Friday 15th November 2013; Alderley Park, Cheshire, UK.

Glinka A., Wiśniowska B. hERG channel trafficking mutations – their role in the drug triggered arrhythmia. Simulation study. BSTP 28th Annual Scientific Meeting held jointly with the Safety Pharmacology Society. Thursday 14th and Friday 15th November 2013; Alderley Park, Cheshire, UK.

Symposium on Cardiac Safety Simulator, Sheffield, UK, 19-20 September 2013.

Polak S., Tomaszewska D., Patel N., Jamei M., Rostami-Hodjegan A. Pharmacokinetic (PK) and pharmacodynamic (PD) implications of diurnal variation of gastric emptying and small intestinal transit time for quinidine: A mechanistic simulation. PAGE conference, 11-14 June 2013, Glasgow, Scotland.

Polak S. In Vitro to Human In Vivo Translation – Proarrhythmic Potency of Dofetilide8th Annual International Conference on Predictive Human Toxicity and ADME/Tox Studies January 24th - 25th, 2013 Brussels, Belgium. 

4th Workshop on using Computational Methods in Pharmaceutical Sciences was a one day long training which took place on 8th of September, 2012 in Krakow, Poland as a part of the Computing in Cardiology Conference - CinC 2012. The main goal of the Workshop was to provide in depth, practical information about design, development, validation and implementation of the computational methods used in the pharmaceutical sciences with focus put on the early drugs cardiotoxicity prediction. Video materials from the event will be available soon.

Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A. In silico prediction of the drug overdose consequences at the heart electrophysiology level. Computing in Cardiology; September 9-12, 2012; Krakow, Poland. Full text in Computing in Cardiology, 2012;39:889-893.

Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A. ToxComp ‐ in vitro–in vivo extrapolation system for the drugs proarrhythmic potency assessment. Computing in Cardiology; September 9-12, 2012; Krakow, Poland. Full text in Computing in Cardiology, 2012;39:789-793.

Polak S, Wisniowska B, Fijorek K, Glinka A, Polak M, Mendyk A. Modeling and Simulation Approach for Assessing Proarrhythmic Potency of the Non‐cardiological Drugs. Computing in Cardiology; September 9-12, 2012; Krakow, Poland. Full text in Computing in Cardiology, 2012;39:761-765.

Mendyk A, Wisniowska B, Fijorek K, Glinka A, Polak M, Polak S. Empirical modeling of the sodium channel inhibition caused by drugs. Computing in Cardiology; September 9-12, 2012; Krakow, Poland. Full text in Computing in Cardiology, 2012;39:293-297.

48th EUROTOX Congress took place in Stockholm, Sweden (17-20 of June, 2012). Team achievements were presented as the scientific posters: "Influence of the physiological parameters on the APD90 value simulated by human ventricular tissue model" and "Electrophysiologically inactive drugs - can we predict their cardiotoxicity?". They both were presented during the Session P07 Computational toxicology.

Mishra H, Jamei M. Rostami-Hodjegan M, Polak S. Model-Based Prediction of Domperidone and Ketoconazole Interaction and its Impact on QTc Prolongation. 21st PAGE meeting; June 5th - tth, 2012; Venice, Italy.

11th World Pharma Congress was a one day long training which took place in Philadelphia, PA (5-7 of June, 2012). On Tuesday 5th of June Dr Sebastian Polak gave presentation "In vitro-in vivo Extrapolation of the Cardiotoxic Effect: Inter-Individual Variability Matters!".

Polak S., Wiśniowska B., Polak M., Szlęk J., Glinka A., Fijorek K. Mendyk A., ToxComp 1.2 – an Open Source iv vitro in vivo extrapolation (IVIVE) system for cardiotoxicity prediction with Marvin plugins embedded. ChemAxon UGM Budapest 2012, May 22-23, Budapest.

Polak S, Mishra H. Combining In Vitro-In Vivo Extrapolation (IVIVE) and Physiologically-Based Pharmacokinetics (PBPK) with Drug Related Risk Assessment - Cardiotoxicity prediction. 7th Annual International Conference on Predictive Human Toxicity and ADME/Tox Studies; January 26th - 27th, 2012; Brussels, Belgium.

The 16th Online World Conference on Soft Computing in Industrial Applications (WSC16); December 5th - 16th, 2011 INTERNET! Team achievements were presented during the special session - Special Session on Soft Computing Methods in Pharmaceutical and Medical Sciences.

On-line workshop 3rd International Workshop - Computational Pharmacy; September 22nd, 2011; Krakow, Poland (Internet!).

Polak S, Glinka A, Wisniowska B, Mendyk A. Influence on the physiological parameters on the ADP90 value simulated by human venrticular tissue model. Eurotox 2011, August 28th - 31st; Paris, France.

Half day long workshop Tox IVIVE - inter-individual variability matters! September 14th - 16th 2011; Berlin, Germany. All materials are available for download here.

Polak S. Optimization of the use of information for in vitro and in silico to predict in vivo Computational toxicology - in silico drug safety assessment during the 3rd Annual Predictive Toxicology; September 14th - 16th 2011; Berlin, Germany.

Mini-symposium Computational toxicology - in silico drug safety assessment during the 3rd Annual Predictive Toxicology; 14-16 September 2011; Berlin, Germany.

Mini-symposium Computational toxicology and pharmacology - in silico drug activity and safety assessment (Saturday, July 2, 11:00) during the 8-th European Conference on Mathematical and Theoretical Biology and Annual Meeting of The Society for Mathematical Biology; June 28th - July 2nd 2011, Krakow, Poland.

Sebastian Polak, Aleksander Mendyk. Computational toxicology. In silico assessment of the hERG channel inhibition potential for the early drug cardiotoxicity testing. Chemaxon 2011 European UGM, Training day and Markush Forum, May 16-19, Budapest, Hungary.

Sebastian Polak, Barbara Wisniowska, Kamil Fijorek, Anna Glinka, Miłosz Polak, Aleksander Mendyk. ToxComp - in silico platform for the cardiotoxicity assessment – in vitro-in vivo extrapolation. Applied Pharmaceutical Toxicology Workshop; May 18 - 20 2011; San Francisco, CA, USA.

Sebastian Polak. Combining systems biology and pharmacokinetics - drug cardiotoxicity assessment. 2011 CellML Workshop. Auckland, 11-12.04.2011 (on line presentation).

Sebastian Polak, Barbara Wisniowska, Malidi Ahamadi, Aleksander Mendyk. Prediction of the hERG potassium channel inhibition potential with use of the artificial neural networks. Soft Computing in Industrial Applications. Algorithms, Integration and Success Stories. In Advances in Intelligent and Soft Computing vol. 75 Eds. Gao X-Z, Gaspar-Cunha A., Koeppen M., Schaefer G., Wang J. Springer, Berlin 2010.

Barbara Wisniowska, Aleksander Mendyk, Milosz Polak, Jakub Szlek, Sebastian Polak. RandomForest based assessment of the hERG channel inhibition potential for the early drug cardiotoxicity testing (polish/english). MCSB 2010, Krakow 21-22.05.2010.

Sebastian Polak, Barbara Wisniowska, Malidi Ahamadi, Aleksander Mendyk. Prediction of the hERG potassium channel inhibition potential with use of the artificial neural networks. 14th Online World Conference on Soft Computing in Industrial Applications (WSC14), 17-29.11.2009.

Sebastian Polak. Modelling and simulations in modern pharmacy – bridging regulatory bodies, academia and industry. 3rd BBBB-Bosphorus International Conference on Pharmaceutical Sciences, Antalya, Turkey 26-28.10.2009; European Journal of Pharmaceutical Sciences 2009, vol. 38, Issue 1, Supplement.

Barbara Wisniowska, Sebastian Polak. Cardiotoxicity prediction algorithms. 1st International Workshop Computational Pharmacy, Krakow 19.06.2009.

Sebastian Polak, Barbara Wisniowska, Jerzy Brandys. Decision trees algorithms for the in silico prediction of hERG potassium channels inhibition (in polish). Polish Society of Toxicology Workshop “New trends in toxicology”, Lodz 1-2.06.2009.

Barbara Wisniowska, Sebastian Polak, Jerzy Brandys. Bayesian classification methods for proarrhythmic liability prediction. 5th German-Polish Symposium “New Challenges for Pharmaceutical Sciences”, Poznan 15-16.05.2009.

Sebastian Polak, Barbara Wisniowska, Jerzy Brandys. Modelling and simulation in the drug discovery, research and development. Toxicity prediction. 5th German-Polish Symposium “New Challenges for Pharmaceutical Sciences”, Poznan 15-16.05.2009.

Barbara Wisniowska, Sebastian Polak, Jerzy Brandys. Extrapolating factors for different in vitro hERG systems. Central European Congress of Life Science EUROBIOTECH 2008, Kraków 17-19.10.2008; Acta Biochimica Polonica 2008, vol. 55 suppl. 4.

-------

We will be presenting

TBA

-------

Technical reports

Polak S, Fijorek K, Püsküllüoğlu M, Glinka A, Tomaszewska D, Tomaszewski R. Literature review of the serum potassium, sodium and calcium levels in healthy individualsTechnical Note, 2013; 001.

-------

We were cited

Le Guennec J-Y et al. Inter-individual variability and modeling of electrical activity: a possible new approach to explore cardiac safety?Scientific Reports, 2016; Article number: 37948.

Didziapetris R, Lanevskij K. Compilation and physicochemical classification analysis of a diverse hERG inhibition databaseJournal of Computer-Aided Molecular Design, 2016; Article First Online: 25 October 2016.

Turner JR et al. Postmarketing Cardiovascular Safety ConsiderationsTurner JR, Karnad DR, Kothari S (eds): Cardiovascular Safety in Drug Development and Therapeutic Use. Switzerland, Springer, 2017.

Muszkiewicz A et al. Variability in cardiac electrophysiology: Using experimentally-calibrated populations of models to move beyond the single virtual physiological human paradigmProgress in Biophysics and Molecular Biology, 2016; Vol. 173, Issue 19: 2819-2832.

Dubois VFS et al. Pharmacokinetic–pharmacodynamic modelling of drug-induced QTc interval prolongation in man: prediction from in vitro human ether-à-go-go-related gene binding and functional inhibition assays and conscious dog studiesBritish Journal of Pharmacology, 2016; Vol. 173, Issue 19: 2819-2832.

Patlewicz G, Fitzpatrick JM. Current and Future Perspectives on the Development, Evaluation, and Application of in Silico Approaches for Predicting ToxicityChemical Research in Toxicology, 2016; Vol. 29: 438-451.

Sasaoka S, et al. Time-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug Events PLOS One, 2016; Published Online: 10 October 2016.

Izumi-Nakaseko H, et al. Assessment of Safety Margin of an Antipsychotic Drug Haloperidol for Torsade de Pointes Using the Chronic Atrioventricular Block Dogs Cardiovascular Toxicology, 2016; First Online: 13 October 2016.

Korur A, et al. QTc prolongation during peripheral stem cell apheresis in healthy volunteers Journal of Clinical Apheresis, 2016; First Published Online: 20 August 2016.

George CH, et al. Pleiotropic mechanisms of action of perhexiline in heart failureExpert Opinion on Therapeutic Patents, 2016; Vol. 26 Issue 9: 1049-1059.

Orsolini L, et al. An update of safety of clinically used atypical antipsychotics Expert Opinion on Drug Safety, 2016; In press, accepted for publication.

Colatsky T, et al. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress Journal of Pharmacological and Toxicological Methods, 2016; In press, accepted for publication.

Nomura F, et al. Predictive lethal proarrhythmic risk evaluation using a closed-loop-circuit cell network with human induced pluripotent stem cells derived cardiomyocytes Japanese Journal of Applied Physics, 2016; In press, accepted for publication.

Page G, et al. Human ex-vivo action potential model for pro-arrhythmia risk assessment Journal of Pharmaceutical and Toxicological Methods, 2016; In press, accepted for publication.

Trame MN, et al. Systems pharmacology to predict drug safety in drug development European Journal of Pharmaceutical Sciences, 2016; In press, accepted for publication.

Blaauboer BJ, et al. Considering new methodologies in strategies for safety assessment of foods and food ingredients Food and Chemical Toxicology, 2016; 91:19–35.

Fujita H, et al. Sudden Cardiac Death (SCD) Prediction based on Nonlinear Heart Rate Variability Features and SCD Index Applied Soft Computing, 2016: [Epub ahead of print].

Picones A, et al. Contribution of Automated Technologies to Ion Channel Drug Discovery Advances in Protein Chemistry and Structural Biology, 2016: [Epub ahead of print].

Davies MR, et al. Recent developments in using mechanistic cardiac modelling for drug safety evaluation Drug Discovery Today, 2016: 21(6): 924-938.

Gintant G, et al. Evolution of strategies to improve preclinical cardiac safety testing. Nature Reviews Drug Discovery, 2016: [Epub ahead of print].

Chavan S, et al. A k-nearest neighbor classification of hERG K+ channel blockers. Journal of Computer-Aided Molecular Design, 2016; pp 1-8 First online: 10 February 2016.

Bergenholm L, et al. PKPD modelling of PR and QRS intervals in conscious dogs using standard safety pharmacology data. Journal of Pharmacological and Toxicological Methods, 2016; 79: 34–44.

Zhang C, et al. In Silico Prediction of hERG Potassium Channel Blockage by Chemical Category ApproachesToxicological Research, 2016; accepted for publication

Schyman P, et al. A General Purpose 2D and 3D Similarity Approach to Identify hERG BlockersJChemInfModel, 2016; accepted for publication.

Poulin P. A Paradigm Shift in Pharmacokinetic–Pharmacodynamic (PKPD) Modeling: Rule of Thumb for Estimating Free Drug Level in Tissue Compared with Plasma to Guide Drug DesignJournal of Pharmaceutical Sciences, 2015; Vol.104 No.7: 2359-2368.

Salloum NA, et al. Assessment of combination therapy in BALB/c mice injected with carbapenem-resistant Enterobacteriaceae strainsFrontiers in Microbiology, 2015; Vol. 6:999.

Tan WJ, et al. Prospective Comparison of the Alvarado Score and CT Scan in the Evaluation of Suspected Appendicitis: A Proposed Algorithm to Guide CT Use. Journal of the American College of Surgeons, 2015; Vol. 220, No. 2, pp: 218-224.

Bentow C, et al. Clinical performance evaluation of a novel, automated chemiluminescent immunoassay, QUANTA Flash CTD Screen Plus. Immunology Research, 2015; Vol. 16, No. 1, pp: 110-116.

Weir MR, Espaillat R. Clinical perspectives on the rationale for potassium supplementationPostgraduate Medicine, 2015; Vol. 127, No. 5,pp: 539-548.

Youssef AJ, et al. Drug-drug interactions in pharmacologic management of gastroparesisNeurogastroenterology & Motility, 2015; Article first published online: 8 JUN 2015.

Klinck J, et al. Predictors and outcome impact of perioperative serum sodium changes in a high-risk populationBr J Anaesth, 2015; 114 (4): 615-622.

Hardeland R. Melatonin and Circadian Oscillators in Aging - A Dynamic Approach to the Multiply Connected PlayersYashin AI, Jazwinski SM (eds): Aging and Health - A Systems Biology Perspective. Interdiscipl Top Gerontol. Basel, Karger, 2015, vol 40, pp 128-140, 2015.

Stimers JR, et al. Overexpression of the Large-Conductance, Ca2+-Activated K+ (BK) Channel Shortens Action Potential Duration in HL-1 CardiomyocytesPLOSOne, 2015. Published: June 19, 2015.

Feric NT, Radisic M. Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissuesAdvanced Drug Delivery Reviews, 2015. Available online 5 May 2015, In Press [Epub ahead of print]

De Mieri M. et al. hERG Channel Inhibitory Daphnane Diterpenoid Orthoesters and Polycephalones A and B with Unprecedented Skeletons from Gnidia polycephalaJNatProd, 2015. [Epub ahead of print]

Du K. et al. HPLC-Based Activity Profiling for hERG Channel Inhibitors in the South African Medicinal Plant Galenia africanaPlanta Med, 2015 Apr 29. [Epub ahead of print]

Vicente J. et al. Comprehensive T wave Morphology Assessment in a Randomized Clinical Study of Dofetilide, Quinidine, Ranolazine, and VerapamilJAHA, 2015; 13(4).

Katagi J, et al. Why Can dl-Sotalol Prolong the QT Interval In Vivo Despite Its Weak Inhibitory Effect on hERG K+ Channels In Vitro? Electrophysiological and Pharmacokinetic Analysis with the Halothane-Anesthetized Guinea Pig ModelCardiovascular Toxicology, 2015, in press.

Collins TA, et al. Modeling and Simulation Approaches for Cardiovascular Function and Their Role in Safety AssessmentCPT:PSP, 2015, 4e18.

Villoutreix BO, Taboureau O. Computational investigations of hERG channel blockers: New insights and current predictive modelsAdvanced Drug Delivery Reviews, 2015, in press.

Gotta V, et al. Sensitivity of pharmacokinetic–pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testingJournal of Pharmacological and Toxicological Methods, 2015;72:1-10.

Torres PJ. A Model for Cell Volume RegulationMathematical Models with Singularities. Atlantis Briefs in Differential Equations, 2015; 1:107-112.

Kauthale RR, et al. Assessment of temperature-induced hERG channel blockade variation by drugsJournal of Applied Toxicology, 2014; EarlyView: Accepted 20th August.

Luo F, et al. Molecular docking and molecular dynamics studies on the structure–activity relationship of fluoroquinolone for the HERG channelMolecular BioSystems, 2014;10:2863-2869.

Anwar-Mohamed A, et al. A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicityToxicology Letters, 2014;230(3):382-392.

Keramati A, et al. Addressing churn prediction problem with Meta-heuristic, Machine learning, Neural Network and data mining techniques: a case study of a telecommunication companyMETAHEURISTICS AND ENGINEERING Proceedings ofthe 15th EU/ME Workshop, Bilecik S¸ eyh Edebali University, 2014 ISBN 978-605-85313- 0-7.

Ferreiro FF, et al. In vivo arrhythmogenicity of the marine biotoxin azaspiracid‑2 in ratsArchives of Toxicology, 2014;88(2):425-434.

Yuan Y. et al. The virtual heart as a platform for screening drug cardiotoxicity. British Journal of Pharmacology, 2014; accepted for publication.

Danker T, Moeller C. Early identification of hERG liability in drug discovery programs by automated patch clamp. Frontiers in Pharmacology. 2014; 5 Article 203.

Nikolov NG, et al. hERG blocking potential of acids and zwitterions characterized by three thresholds for acidity, size and reactivity Bioorganic & Medicinal Chemistry. 2014;22(21):6004–6013.

Severi, S, Rodriguez B, Zaza A. Computational cardiac electrophysiology is moving towards translation medicine Europace. 2014;16(5):703-704.

Braga, RC et al. Tuning hERG Out: Antitarget QSAR Models for Drug Development Current Topics in Medicinal Chemistry. 2014;14(11):1399-1415.

Torres, PJ. Periodic oscillations of a model for membrane permeability with fluctuating environmental conditions. Journal of Mathematical Biology. 2014;[Epub ahead of a print].

Kaneko T, et al. On-chip in vitro cell-network pre-clinical cardiac toxicity using spatiotemporal human cardiomyocyte measurement on a chip. Scientific Reports. 2014:4670.

Dallmann R, Brown SA, Gachon F. Chronopharmacology: New Insights and Therapeutic Implications. Annual Review of Pharmacology and Toxicology. 2014;54:339-361.

Ekins S. Progress in computational toxicology. Journal of Pharmacological and Toxicological Methods. 2014;69(2):115-140.

Sliwoski G. et al. Computational Methods in Drug Discovery. Pharmacological Reviews. 2014;66(1):334-395.

Czodrowski P. hERG Me Out. JChemInfModel. 2013;53(9):2240-2251.

Xuan SY, et al. Classification of blocker and non-blocker of hERG potassium ion channel using a support vector machine. Science China Chemistry. 2013;56(10):1413-1423.

Ferreiro SR, et al. In vivo arrhythmogenicity of the marine biotoxin azaspiracid-2 in rats. Arch Toxicol. 2013; published on line 23 June.

Nunes SS, et al. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nature Methods. 2013; 10:781–787.

Wang S, Lia Y, Xua L, Lib D, Hou T. Recent Developments in Computational Prediction of hERG Blockage. Current Topics in Medicinal Chemistry. 2013;13.

Shah RR, Gussak I. Acquired (Drug-Induced) Long and Short QT Syndromes. 2013; in Gussak I and Antzelevitch C. Electrical Diseases of the Heart. Volume 2: Diagnosis and Treatment. London, UK: Springer-Verlag.

Di Veroli  GY, Davies MR, Zhang H, Abi-Gerges N, Boyett MR. High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment. Am J Physiol Heart Circ Physiol. 2013;304:H104-H117.

Danielsson BR. Maternal Toxicity. Teratogenicity Testing. Methods in Molecular Biology. 2013;947:311-325.

Miyara M et al. Clinical Phenotypes of Patients with Anti-Dfs70/Ledgf Antibodies in A Routine ANA Referral Cohort Clinical and Developmental Immunology. 2013; art. no. 703759.

Swart A, Burlingame RW, Gürtler I, Mahler M. Third generation anti-citrullinated peptide antibody assay is a sensitive marker in rheumatoid factor negative rheumatoid arthritis Clinica Chimica Acta. 2012;414:266-272.

Broccatelli F, Mannhold R, Moriconi A,Giuli S, Carosati E. QSAR modeling and data mining link torsades de pointes risk to the interplay of extent of metabolism, active transport, and hERG liability Molecular Pharmaceutics. 2012;9(8):2290-2301.

Kireeva N, Kuznetsov SL, Bykow AA, Tsivadze AY. Towards in silico identification of the human ether-a-go-go-related gene channel blockers: discriminative vs. generative classification models. SAR and QSAR in Environmental Research. 2012;24(2).

Wang S, Li Y, Wang J, Chen L, Zhang L, Yu H, Hou T. ADMET Evaluation in Drug Discovery. 12. Development of Binary Classification Models for Prediction of hERG Potassium Channel Blockage. Molecular Pharmaceutics. 2012;9:996-1010.

Mirams GR, Davies MR, Cui Y, Kohl P, Noble D. Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing. British Journal of Pharmacology. 2012;167(5):932-945.

Eichenbaum G, Pugsley MK, Gallacher DJ, Towart R, McIntyre G, Shukla U, Davenport JM, Lu HR, Rohrbacher J, Hillsamer V. Role of Mixed Ion Channel Effects in the Cardiovascular Safety Assessment of the Novel Anti-MRSA Fluoroquinolone JNJ-Q2. British Journal of Pharmacology. 2012; 166(5):1694-1707.

Gleeson MP, Modi S, Bender A, Robinson RL, Kirchmair J, Promkatkaew M, Hannongbua S, Glen RC. The Challenges Involved in Modeling Toxicity Data In Silico: A Review. Current Pharmaceutical Design. 2012;18(9):1266-1291.

Hishigaki H, Kuhara S. hERGAPDbase: a database documenting hERG channel inhibitory potentials and APD-prolongation activities of chemical compounds. Database: The Journal of Biological Databases and Curation. 2011; published online May 17th.

Migliorini C, Lave T, Parrott NJ, Reddy M, Grimm HP, Penland RC, Soubret A, Helmlinger G, Georgieva A, Zuideveld KP. Systems Toxicology Modeling for Prediction in Humans. 2011; in Sahu SC et al. General, Applied and System Toxicology. Chichester, West Sussex, U.K: John Wiley & Sons.

Tan Y, Chen Y, You Q, Sun H, Li M. Predicting the potency of hERG K+ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models. Journal of Molecular Modeling. 2011; 18(3):1023-1036.

Su Z, Gintant G. Preclinical Drug Safety and Cardiac Ion Channel Screening. Heart Rate and Rhythm. 2011;Part 7:627-638.

Church MK. Safety and efficacy of bilastine: a new H1-antihistamine for the treatment of allergic rhinoconjunctivitis and urticaria. Expert Opinion on Drug Safety. 2011;10(5):779-793.

Schuster AM, Glassmeier G, Bauer CK. Strong activation of erg1 K+ channel isoforms by NS1643 (1,3-bis-(2-hydroxy-5-trifluoromethylphenyl)-urea) in HEK-293 and CHO cells. Molecular Pharmacology. 2011; August 19th: available online.

Schramm A, Baburin I, Hering S, Hamburger M. HERG channel inhibitors in extracts of coptidis rhizoma. Planta Medica. 2011;77(7):692-697.

Taboureau O, Jørgensen FS. In silico Predictions of hERG Channel Blockers in Drug Discovery: From Ligand-Based and Target-Based Approaches to Systems Chemical Biology. Comb Chem High Throughput Screen. 2011;14(5):375-87.

Marchese Robinson RL, Glen RC, Mitchell JBO. Development and Comparison of hERG Blocker Classifiers: Assessment on Different Datasets Yields Markedly Different Results. Molecular Informatics. 2011;30(5):443-458.

Obiol-Pardo C, Gomis-Tena J, Sanz F, Saiz J, Pastor M. A Multiscale Simulation System for the Prediction of Drug-Induced Cardiotoxicity. Journal of Chemical Information and Modeling. 2011;51(2):483-492.

Beyer BK, Chernoff N, Danielsson BR, et al. ILSI/HESI maternal toxicity workshop summary: maternal toxicity and its impact on study design and data interpretation. Birth Defects Research Part B - Developmental and Reproductive Toxicology. 2011;92(1):36-51.

Schmalhofer WA, Swensen AM, Thomas BS, et al. A Pharmacologically Validated, High-Capacity, Functional Thallium Flux Assay for the Human Ether-á-go-go Related Gene Potassium Channel. Assay and Drug Development Technologies. 2010;8(6):714-726

Huang XP, Mangano T, Hufeisen S, Setola V, Roth BL. Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. Assay and Drug Development Technologies. 2010;8(6):727-42.

Sprous D.G., Palmer R.K., Swanson J.T., Lawless M. QSAR in the pharmaceutical research setting: QSAR models for broad, large problems. Curr. Top. Med. Chem. Current Topics in Medicinal Chemistry. 2010;10(6):619-637.

Sprous D, Palmer K. The T1R2/T1R3 Sweet Receptor and TRPM5 Ion Channel: Taste Targets with Therapeutic Potential. Progress in Molecular Biology and Translational Science. 2010;91:151-208.

Raschi E., De Ponti F., Ceccarini L., Recanatini M. HERG-related drug toxicity and models for predicting hERG liability and QT prolongation. Expert Opinion on Drug Metabolism and Toxicology. 2009;5(9):1005-1021.